{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:52:34Z","timestamp":1792590754365,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["154321"],"award-info":[{"award-number":["154321"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["192044"],"award-info":[{"award-number":["192044"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["OG-3- 24-5819-DD"],"award-info":[{"award-number":["OG-3- 24-5819-DD"]}],"id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xcrm.2025.102511","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:36:26Z","timestamp":1765899386000},"page":"102511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Glucagon-like peptide-1 medicines in neurological and psychiatric disorders"],"prefix":"10.1016","volume":"6","author":[{"given":"Susanna","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6688-8127","authenticated-orcid":false,"given":"Daniel J.","family":"Drucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102511_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2025.102511_bib2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: from basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.xcrm.2025.102511_bib3","article-title":"The expanding benefits of GLP-1 medicines","volume":"6","author":"Gonzalez-Rellan","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2025.102511_bib4","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s42255-025-01295-w","article-title":"GIPR-Ab\/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice","volume":"7","author":"Liu","year":"2025","journal-title":"Nat. Metab."},{"key":"10.1016\/j.xcrm.2025.102511_bib5","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2025.102511_bib6","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s42255-025-01342-6","article-title":"Fluorescent GLP1R\/GIPR dual agonist probes reveal cell targets in the pancreas and brain","volume":"7","author":"de Bray","year":"2025","journal-title":"Nat. Metab."},{"key":"10.1016\/j.xcrm.2025.102511_bib7","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/ijo.2015.136","article-title":"Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes","volume":"39","author":"Christensen","year":"2015","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.xcrm.2025.102511_bib8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102511_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4093\/dmj.2019.0018","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus","volume":"44","author":"Bae","year":"2020","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.xcrm.2025.102511_bib10","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102511_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.xcrm.2025.102511_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","article-title":"Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease","volume":"28","author":"Nowell","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.xcrm.2025.102511_bib13","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102511_bib14","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.90633","article-title":"Lost in translation: Inconvenient truths on the utility of mouse models in Alzheimer's disease research","volume":"13","author":"Granzotto","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.xcrm.2025.102511_bib15","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.xcrm.2025.102511_bib16","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers","volume":"122","author":"Bomfim","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102511_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1462240","article-title":"Neuroprotective effects of GLP-1 class drugs in Parkinson's disease","volume":"15","author":"Lv","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.xcrm.2025.102511_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.xcrm.2025.102511_bib19","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1021\/acsptsci.1c00013","article-title":"Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease","volume":"4","author":"Wang","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.xcrm.2025.102511_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177972","article-title":"The novel GLP-1\/GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson's disease","volume":"1003","author":"Feng","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102511_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-2094-5-19","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.xcrm.2025.102511_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","article-title":"The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease","volume":"15","author":"Long-Smith","year":"2013","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.xcrm.2025.102511_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102019","article-title":"The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice","volume":"89","author":"Forny Germano","year":"2024","journal-title":"Mol. Metab."},{"key":"10.1016\/j.xcrm.2025.102511_bib24","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"Norgaard","year":"2022","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.xcrm.2025.102511_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102689","article-title":"Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study","volume":"73","author":"Tang","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.xcrm.2025.102511_bib26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamaneurol.2025.0360","article-title":"Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis","volume":"82","author":"Seminer","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.xcrm.2025.102511_bib27","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.xcrm.2025.102511_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113537","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.xcrm.2025.102511_bib29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/pds.5448","article-title":"Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes","volume":"31","author":"Sunnarborg","year":"2022","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.xcrm.2025.102511_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107132","article-title":"Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study","volume":"128","author":"Rozani","year":"2024","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.xcrm.2025.102511_bib31","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/mds.29992","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study","volume":"39","author":"Tang","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.xcrm.2025.102511_bib32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.xcrm.2025.102511_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","article-title":"Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)","volume":"20","author":"Femminella","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.xcrm.2025.102511_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/alz.057848","article-title":"Evaluation of liraglutide in the treatment of Alzheimer's disease","volume":"17","author":"Edison","year":"2021","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.xcrm.2025.102511_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.xcrm.2025.102511_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081401","article-title":"Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults","volume":"14","author":"Koychev","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.xcrm.2025.102511_bib37","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102511_bib38","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102511_bib39","article-title":"A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson\u2019s Disease","author":"Hogg","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102511_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2025.102511_bib41","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of Lixisenatide in Early Parkinson\u2019s Disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102511_bib42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10072-024-07701-7","article-title":"Multiple sclerosis patients taking glucagon-like peptide-1 receptor (GLP-1) agonists: a single-institution retrospective cohort study of tolerability and weight loss","volume":"46","author":"Udawatta","year":"2025","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.xcrm.2025.102511_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106229","article-title":"Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort","volume":"93","author":"Balshi","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.xcrm.2025.102511_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311162","article-title":"Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance","volume":"24","author":"Hardonova","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2025.102511_bib45","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/ana.70004","article-title":"Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy","volume":"98","author":"Vijiaratnam","year":"2025","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2025.102511_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107078","article-title":"IUPHAR Review: New strategies for medications to treat substance use disorders","volume":"200","author":"Montoya","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.xcrm.2025.102511_bib47","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1044\/jshr.3605.883","article-title":"F2 transitions during sound\/syllable repetitions of children who stutter and predictions of stuttering chronicity","volume":"36","author":"Yaruss","year":"1993","journal-title":"J. Speech Hear. Res."},{"key":"10.1016\/j.xcrm.2025.102511_bib48","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf141","article-title":"GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer","volume":"9","author":"Srinivasan","year":"2025","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.xcrm.2025.102511_bib49","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1038\/s41380-020-00957-3","article-title":"GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA","volume":"26","author":"Hernandez","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.xcrm.2025.102511_bib50","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.xcrm.2025.102511_bib51","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/adb.12583","article-title":"Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats","volume":"24","author":"Hernandez","year":"2019","journal-title":"Addict. Biol."},{"key":"10.1016\/j.xcrm.2025.102511_bib52","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2025.102511_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.68","article-title":"The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.xcrm.2025.102511_bib54","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.xcrm.2025.102511_bib55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder","volume":"82","author":"Lahteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.xcrm.2025.102511_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2025.102511_bib57","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2025.102511_bib58","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.xcrm.2025.102511_bib59","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102511_bib60","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102511_bib61","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102511_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr5051","article-title":"An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking","volume":"11","author":"Merkel","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2025.102511_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.xcrm.2025.102511_bib64","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7326\/M23-2718","article-title":"Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data","volume":"177","author":"Wang","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.xcrm.2025.102511_bib65","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.xcrm.2025.102511_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.xcrm.2025.102511_bib67","article-title":"Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial","volume":"97","author":"Yammine","year":"2018","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.xcrm.2025.102511_bib68","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study","volume":"29","author":"Wang","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.xcrm.2025.102511_bib69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2016.02.003","article-title":"Neurobehavioral effects of liraglutide and sitagliptin in experimental models","volume":"774","author":"Kamble","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102511_bib70","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.psyneuen.2015.11.021","article-title":"GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality","volume":"65","author":"Anderberg","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.xcrm.2025.102511_bib71","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00702-019-02084-y","article-title":"Animal models of major depression: drawbacks and challenges","volume":"126","author":"Planchez","year":"2019","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.xcrm.2025.102511_bib72","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s13300-020-00985-w","article-title":"Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial","volume":"12","author":"Ishii","year":"2021","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.xcrm.2025.102511_bib73","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jdiacomp.2011.03.002","article-title":"Psychological and quality of life changes in patients using GLP-1 analogues","volume":"25","author":"Grant","year":"2011","journal-title":"J. Diabetes Complications"},{"key":"10.1016\/j.xcrm.2025.102511_bib74","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1463-1326.2010.01196.x","article-title":"Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes","volume":"12","author":"Bode","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.xcrm.2025.102511_bib75","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.xcrm.2025.102511_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116592","article-title":"Efficacy and safety of GLP1-ras compared to SGLT2is and DPP-4is in individuals with schizophrenia and diabetes: A Danish nationwide target-trial emulation study","volume":"351","author":"Jacobsen","year":"2025","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.xcrm.2025.102511_bib77","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study","volume":"207","author":"Mansur","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.xcrm.2025.102511_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2025.102511_bib79","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1111\/dom.70002","article-title":"Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population-based cohort study","volume":"27","author":"Her","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.xcrm.2025.102511_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2025-301635","article-title":"Use of GLP-1 receptor agonists and risks of suicide attempts or self-harm in patients with type 2 diabetes: a multicountry self-control case series study","volume":"28","author":"Peng","year":"2025","journal-title":"BMJ Ment. Health"},{"key":"10.1016\/j.xcrm.2025.102511_bib81","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080679","article-title":"Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study","volume":"388","author":"Shapiro","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.xcrm.2025.102511_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103029","article-title":"Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study","volume":"80","author":"Bezin","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.xcrm.2025.102511_bib83","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/s00125-024-06243-z","article-title":"Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study","volume":"67","author":"Hurtado","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.xcrm.2025.102511_bib84","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamapediatrics.2024.3812","article-title":"Risk of Suicidal Ideation or Attempts in Adolescents With Obesity Treated With GLP1 Receptor Agonists","volume":"178","author":"Kerem","year":"2024","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.xcrm.2025.102511_bib85","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102511_bib86","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12974-019-1638-6","article-title":"The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke","volume":"16","author":"Shan","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.xcrm.2025.102511_bib87","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1161\/STROKEAHA.116.012934","article-title":"Exendin-4 Inhibits Matrix Metalloproteinase-9 Activation and Reduces Infarct Growth After Focal Cerebral Ischemia in Hyperglycemic Mice","volume":"47","author":"Kuroki","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.xcrm.2025.102511_bib88","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xcrm.2025.102511_bib89","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102511_bib90","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/17474930241253988","article-title":"Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"19","author":"Adamou","year":"2024","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.xcrm.2025.102511_bib91","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.xcrm.2025.102511_bib92","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102511_bib93","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.21016","article-title":"Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity","volume":"8","author":"Lin","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.xcrm.2025.102511_bib94","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000475","article-title":"2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association\/American Stroke Association","volume":"55","author":"Bushnell","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.xcrm.2025.102511_bib95","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11010-016-2678-1","article-title":"Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice","volume":"415","author":"Koshal","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.xcrm.2025.102511_bib96","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102511_bib97","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/epi4.13091","article-title":"Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis","volume":"9","author":"Sindhu","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.xcrm.2025.102511_bib98","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/head.14991","article-title":"Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: A prospective pilot study","volume":"65","author":"Braca","year":"2025","journal-title":"Headache"},{"key":"10.1016\/j.xcrm.2025.102511_bib99","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaneurol.2025.2020","article-title":"GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension","volume":"82","author":"Sioutas","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.xcrm.2025.102511_bib100","first-page":"1034","article-title":"Impact of GLP-1 receptor agonists on idiopathic intracranial hypertension clinical and neurosurgical outcomes: a propensity-matched multi-institutional cohort study","volume":"143","author":"O'Leary","year":"2025","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.xcrm.2025.102511_bib101","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/brain\/awad003","article-title":"The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial","volume":"146","author":"Mitchell","year":"2023","journal-title":"Brain"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:51:09Z","timestamp":1790265069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125005841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":101,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666379125005841"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102511","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 medicines in neurological and psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102511"}}